GSK Closes Stevenage Site Five Years After Expansion Pledge

GSK will cut jobs while closing its Stevenage research site and shifting more than 1,000 scientists to a new Cambridge campus. The company framed the changes as part of a £400 million UK investment within a wider £1.9 billion cost-reduction programme targeting annual savings of that amount by 2029.

The Stevenage facility received a £400 million expansion commitment only five years earlier. Its closure by 2029 reverses that plan and concentrates activity in the Cambridge-Oxford-London corridor. GSK stated it will launch 20 phase 3 trials, double the earlier target, but provided no figure for total redundancies.

Forty-five percent of the savings will come from cutting support services and simplifying processes. Another forty percent will come from reducing resources allocated to established treatments. These measures fund the Cambridge move and the accelerated trial programme under new chief executive Luke Miels.

AstraZeneca paused major UK projects in 2025 over drug pricing and NHS access before reversing course with a smaller Cambridge expansion. GSK’s announcement drew praise from the prime minister and Andy Burnham as a vote of confidence. Share prices rose six percent on the day.

The pattern shows repeated corporate consolidation rather than net expansion. Life sciences activity concentrates in one established cluster while sites outside it close and headcount reductions offset new spending. Official statements treat any announced capital commitment as evidence of sector strength.

Britain’s life sciences base now depends on firms reallocating existing activity and trimming overhead to meet global return targets. No data in the announcement indicates an increase in total UK scientific employment or new facilities beyond the Cambridge relocation.

This approach sustains headline investment figures while the underlying conditions that prompted AstraZeneca’s earlier pause remain unaddressed. GSK’s restructuring demonstrates how UK-based multinationals respond when domestic market and regulatory settings constrain growth.